Tipsheet
What matters at India’s listed companies
Pharmaceuticals · Micro cap

Wanbury pays off ₹180 cr NCDs five years early

Board approves early redemption in full of 12.5% secured NCDs originally maturing in 2030, wiping out a substantial debt ahead of schedule.

4 earlier stories on Wanbury Ltd.
Mkt cap₹959 cr
P/E22.30×
ROE51.51%
Debt / eq.2.92
₹180 crore Outstanding principal of NCDs being redeemed early

What's new

  • Wanbury's board passed a resolution on July 15, 2026 to fully redeem 12.5% NCDs early.
  • The NCDs were issued in Feb and Oct 2025, originally maturing on Feb 28, 2030.
  • Record date set as June 20, 2026; exact date to be mutually agreed with debenture holders.

Why this matters

The early redemption eliminates a debt equal to about 15% of market cap, sharply reducing interest outgo and financial risk. It signals improved liquidity and management’s confidence in cash flows — a significant positive surprise for a micro-cap pharma firm.

What we're watching

  • Whether the company provides more details on the funding source for the redemption.
  • Impact on interest cost and net profit from FY27 onwards.
  • Any follow-up debt reduction or further deleveraging plans.

The full read

Wanbury’s board cleared a complete early redemption of ₹180 crore worth of 12.5% secured NCDs. Debt is falling. The move wipes out a liability equal to roughly 15% of the company's market cap, a material deleveraging event for a micro-cap pharma firm carrying a debt-to-equity of 2.92. The early pay-off slashes interest costs and strengthens the balance sheet, fresh on the heels of a 24% pledge release and regulatory progress on three APIs for Australia. It is a confident use of cash flow and a positive surprise the market had not priced in.

Questions answered

Why is Wanbury redeeming its NCDs early?
Wanbury said the early redemption was approved by the board, likely to reduce interest costs and signal improved liquidity. The move comes after recent positive developments like a pledge release and regulatory clearance for Australian API exports.
How much debt is being paid off and at what interest rate?
The NCDs carry a 12.5% coupon, and the outstanding principal is ₹180 crore, roughly 15% of the company’s market capitalisation.
Does Wanbury have the cash to redeem these debentures?
The board’s approval implies that the company has arranged or expects to have the necessary funds. The exact redemption date will be mutually agreed with debenture holders, suggesting a short time frame to arrange liquidity.
What was the original maturity of these NCDs?
The NCDs were originally due on February 28, 2030, so the early redemption is about 3.5 years ahead of schedule.
Mentioned: Wanbury Ltd · ₹180 crore 12.5% NCDs · Early redemption
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Wanbury Ltd.

Pharmaceuticals
₹1,038 cr
P/E 24.15×

Latest quarter · Jun 2025

Sales₹163 cr
Net profit₹13 cr
Op. margin+15.0%
EPS₹4.10

Strength & growth

Debt / equity2.92×
Current ratio1.11×
Sales CAGR+4.4%
EPS CAGR−9.4%
  1. 15 Jul 2026 · 5:45 PM IST Wanbury pays off ₹180 cr NCDs five years early
  2. 6d ago Wanbury's 24% pledge release removes forced-sale overhang
  3. 35d ago Wanbury clears TGA inspection, nears entry into Australia with three APIs
  4. 36d ago Wanbury files for new API markets in Malaysia, Singapore, Korea
  5. 43d ago Wanbury's full-year profit jumps 117% on better mix and procurement savings